PMS-TERAZOSIN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE)

Mevcut itibaren:

PHARMASCIENCE INC

ATC kodu:

G04CA03

INN (International Adı):

TERAZOSIN

Doz:

2MG

Farmasötik formu:

TABLET

Kompozisyon:

TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 2MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

ALPHA-ADRENERGIC BLOCKING AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0136978002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2001-02-23

Ürün özellikleri

PRODUCT MONOGRAPH
PR
PMS-
TERAZOSIN
Terazosin Tablets (as Terazosin Hydrochloride), House Standard
1 mg, 2 mg, 5 mg and 10 mg
Antihypertensive Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
Date of Revision:
November 10, 2023
Submission Control No: 276154
_pms-TERAZOSIN Product Monograph _
_Page 2 of 38 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
13
OVERDOSAGE
................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 15
STORAGE AND STABILITY
.........................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 17
PART II: SCIENTIFIC INFORMATION
...............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
CLINICAL TRIALS
.......................................................